Erastin2 is a ferroptosis inducer and an inhibitor of the system xc- cystine/glutamate transporter.[1] [2] It inhibits glutamate release in CCF-STTG1 cells (IC50 = 0.0035 µM).[2] It induces cell death in HAP1 cells when used at a concentration of 5 µM, an effect that can be blocked by the ferroptosis inhibitor ferrostatin-1 or deferoxamine . [1] Erastin2 also induces ferroptotic cell death in HT-1080 cells (EC50 = 0.15 µM), an effect that can be blocked by the reducing agent β-mercaptoethanol (EC50 = >20 µM). [3] It increases lipid peroxidation in HT-1080 cells when used at a concentration of 1 µM.

Reference:
[1]. Cao, J.Y., Poddar, A., Magtanong, L., et al. A genome-wide haploid genetic screen identifies regulators of glutathione abundance and ferroptosis sensitivity. Cell Rep. 26(6), 1544-1556 (2019).
[2]. Dixon, S.J., Patel, D.N., Welsch, M., et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3, e02523 (2014).
[3]. Magtanong, L., Ko, P.-J., To, M., et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem. Biol. 26(3), 420-432 (2019).